1. HIV-1 Pol Gene Polymorphism and Antiretroviral Resistance Mutations in Treatment-Naive Adult Patients in French Guiana Between 2006 and 2012
- Author
-
Anne Lavergne, Leila Adriouch, Félix Djossou, Myriam El Guedj, Mathieu Nacher, Vincent Lacoste, Alain Berlioz-Arthaud, Edith Darcissac, Pierre Couppié, Rachida Boukhari, Edouard Tanguy, Emmanuelle Papot, Vincent Vantilcke, Damien Donato, Jean-François Pouliquen, Institut Pasteur de la Guyane, Réseau International des Instituts Pasteur (RIIP), Centre d'Investigation Clinique Antilles-Guyane (CIC - Antilles Guyane), Université des Antilles et de la Guyane (UAG)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Centre Hospitalier de l'Ouest Guyanais Franck Joly (Saint-Laurent-du-Maroni), Unité des Maladies Infectieuses et Tropicales [Cayenne, Guyanne Française], This work was funded by the Institut Pasteur de la Guyane. It has also benefited from a European commission REGPOT-CT-2011-285837-STRonGer grant within the FP7, The authors thank Nathalie Jolly from the Institut Pasteur Clinical Research Department (PIRC, Pôle Intégré de Recherche Clinique) for her help in the ethical aspects of the project. They also thank Ketty Bienvenu, Lidia Saint Louis, Sergine Soyon, and Karine Verin for their invaluable assistance., European Project: 285837,EC:FP7:REGPOT,FP7-REGPOT-2011-1,STRONGER(2011), Lacoste, Vincent, Strengthening transdisciplinary research on infectious and emerging diseases in French Guiana: linking fieldwork, benchside and bedside - STRONGER - - EC:FP7:REGPOT2011-11-01 - 2015-04-30 - 285837 - VALID, and CHU de Fort de France-Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française]-CHU Pointe-à-Pitre/Abymes [Guadeloupe] -Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles et de la Guyane (UAG) more...
- Subjects
0301 basic medicine ,Male ,[SDV]Life Sciences [q-bio] ,HIV Infections ,Drug resistance ,MESH: Genotype ,0302 clinical medicine ,MESH: HIV Protease/genetics ,HIV Protease ,MESH: HIV-1/growth & development ,Polymorphism (computer science) ,Genotype ,030212 general & internal medicine ,Genetics ,[SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,MESH: Aged ,MESH: HIV Infections/epidemiology ,Molecular Epidemiology ,MESH: Middle Aged ,Incidence (epidemiology) ,MESH: HIV Infections/drug therapy ,Middle Aged ,Viral Load ,MESH: HIV Infections/virology ,MESH: HIV-1/genetics ,HIV Reverse Transcriptase ,3. Good health ,French Guiana ,[SDV] Life Sciences [q-bio] ,MESH: HIV Protease Inhibitors/therapeutic use ,Infectious Diseases ,[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology ,Reverse Transcriptase Inhibitors ,Female ,Viral load ,Adult ,MESH: French Guiana/epidemiology ,Immunology ,Biology ,MESH: Reverse Transcriptase Inhibitors/therapeutic use ,MESH: Drug Resistance, Viral/genetics ,03 medical and health sciences ,MESH: Polymorphism, Genetic ,MESH: Viral Load/drug effects ,Acquired immunodeficiency syndrome (AIDS) ,Virology ,Drug Resistance, Viral ,medicine ,Humans ,MESH: Molecular Epidemiology ,MESH: HIV Reverse Transcriptase/genetics ,Aged ,Retrospective Studies ,Genetic diversity ,Polymorphism, Genetic ,MESH: Humans ,Molecular epidemiology ,MESH: Adult ,MESH: Retrospective Studies ,HIV Protease Inhibitors ,medicine.disease ,MESH: Male ,030104 developmental biology ,[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie ,Mutation ,HIV-1 ,MESH: Mutation ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,MESH: Female ,MESH: HIV-1/drug effects - Abstract
International audience; Little information is available on the molecular epidemiologic profile of HIV-1 in French Guiana, the French department with the highest HIV/AIDS incidence. To follow the evolution of HIV-1 diversity, we carried out a molecular analysis of HIV-1 isolates from 305 treatment-naive patients between 2006 and 2012. Protease and reverse-transcriptase sequences were obtained for subtype characterization, polymorphism analysis, and identification of drug resistance mutations. Of 305 HIV-1 strains, 95.1% were subtype B viruses. The overall prevalence of transmitted drug-resistance mutations (TDRMs) was 4.6% (14/305), ranging from 1.9% to 7.1% depending on the year. This study shows a low level of HIV-1 genetic diversity and a moderate prevalence of TDRMs with no evidence of an increasing trend over the study period. Nevertheless, the strong genetic polymorphism observed on both genes may be of concern for long-term treatment of people living with HIV-1 and thus deserves continuous monitoring. more...
- Published
- 2016
- Full Text
- View/download PDF